Key Finding: Two exceptional Tier 1 opportunities with 12-year diagnostic delays and massive underdiagnosis. Cosentyx (AS-focused) offers the largest addressable market (450K-750K USA patients, 90% undiagnosed). Fabhalta (PNH) offers the highest per-patient value ($178K-566K annually).
| Drug | Condition | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity (USA, 1-5%) |
|---|---|---|---|---|---|
| Cosentyx (AS-focused) |
Ankylosing Spondylitis | TIER 1 | 8.5/10 | 450K-750K | $17.3M-288M |
| Fabhalta | Paroxysmal Nocturnal Hemoglobinuria | TIER 1 | 7.5/10 | 45-750 | $6.4K-810K |
| Kesimpta | Relapsing Multiple Sclerosis | TIER 2 | 6.5/10 | 15K-44K | $1.06M-4.65M |
| Ilaris | Autoinflammatory Diseases | TIER 2 | 6.0/10 | 500-2,000 | Small (ultra-rare) |
| Scemblix | Chronic Myeloid Leukemia | TIER 3 | 4.5/10 | 400-900 | $32K-648K |
| Jakavi | Myelofibrosis | TIER 3 | 4.0/10 | 50-150 | $8K-90K |
| Lutathera | Advanced GEP-NETs | TIER 3 | 3.5/10 | Small | Small |
| Entresto | Heart Failure | NO | 3/10 | N/A | Generic competition Q3 2025 |
| Kisqali | Breast Cancer | NO | 4/10 | N/A | Well-screened (mammography) |
| Pluvicto | Prostate Cancer (mCRPC) | NO | 2/10 | N/A | Late-stage treatment |
| Leqvio | ASCVD / Cholesterol | NO | 3/10 | N/A | Screening routine |
| + 6 additional drugs marked NO (see full analysis) | |||||
Diagnostic Delay: 12 years average from symptom onset to diagnosis
Key Symptoms (Inflammatory Back Pain):
Common Misdiagnoses: Mechanical back pain, disc herniation, osteoarthritis, fibromyalgia, "just aging"
Ada Surface Ability: 9/10 — Inflammatory back pain criteria are highly specific and can reliably flag suspected AS for rheumatology referral
| USA Addressable | 450,000-750,000 patients |
| Revenue/Patient | $48,000-64,000/year |
| Ada Fee | $3,840-7,680 per patient |
| Total Opportunity (100%) | $1.73B-5.76B |
| At 1% Penetration | $17.3M-57.6M/year |
| At 5% Penetration | $86.4M-288M/year |
Why Tier 1:
Diagnostic Delay: 12+ years (substantial odyssey)
Key Symptoms:
Common Misdiagnoses: Generic anemia, aplastic anemia, other hemolytic anemias
Ada Surface Ability: 6/10 — Dark urine + fatigue + dyspnea + abdominal pain = suggestive pattern, though symptoms overlap with common anemia
| USA Addressable | 45-750 patients |
| Revenue/Patient | $178,000-566,500/year |
| Ada Fee | $14,240-21,600 per patient |
| Total Opportunity (100%) | $640K-16.2M |
| At 1% Penetration | $6.4K-162K/year |
| At 5% Penetration | $32K-810K/year |
Why Tier 1:
Diagnostic Delay: 1-2 years (relatively short)
Key Symptoms: Vision problems, numbness/tingling, weakness, walking difficulties, cognitive changes
Ada Surface Ability: 7/10 — Good symptom pattern (vision + numbness + weakness)
| USA Addressable | 15,000-44,000 patients |
| Revenue/Patient | $88,000/year |
| Total Opportunity (100%) | $105.6M-464.6M |
| At 1% Penetration | $1.06M-4.65M/year |
| At 5% Penetration | $5.28M-23.2M/year |
Why Tier 2: Large addressable market and good symptom recognition, but shorter diagnostic delays and company focus on switching (not finding undiagnosed) makes it secondary to AS and PNH.
Indications: CAPS, TRAPS, HIDS/MKD, FMF, Still's Disease (AOSD/SJIA)
Prevalence: Ultra-rare conditions (1-2 per million for most)
USA Addressable: 500-2,000 patients across all indications
Key Symptoms: Recurrent fevers (periodic, not infection), rash during episodes, joint pain/swelling, elevated inflammatory markers
Diagnostic Delay: Years of diagnostic odyssey common, misdiagnosed as recurrent infections
Ada Surface Ability: 7/10 — Recurrent fever pattern is specific
Revenue/Patient: $100K-200K/year (high orphan drug pricing)
Challenge: Very small absolute numbers across multiple ultra-rare conditions
Opportunity: High per-patient value justifies Patient Finder despite small numbers
Why Tier 2: Ultra-rare with diagnostic odysseys and specific symptom patterns (recurrent fever + rash), but very small absolute numbers limits scale.
2025 Revenue: $1.285B (+87% cc) | Fit Score: 4.5/10
Why Tier 3: CML diagnosed via routine CBC (minimal underdiagnosis 5-10%). Novartis focused on switching patients from other TKIs, not finding undiagnosed. Addressable: 400-900 USA. Ada opportunity: $32K-648K at 1-5% penetration.
2024 Revenue: $1.936B | Fit Score: 4.0/10 | Patent Expiry: 2027
Why Tier 3: Ultra-rare (1 in 100K), requires CBC and bone marrow biopsy. Small absolute numbers (50-150 addressable USA). Patent expiry 2027 reduces long-term value. Ada opportunity: $8K-90K at 1-5%.
2025 Revenue: ~$850M est. | Fit Score: 3.5/10
Why Tier 3: Treats advanced GEP-NETs in already-diagnosed patients (similar to Pluvicto issue). Late-stage treatment, not diagnostic opportunity. Small addressable undiagnosed population.
Entresto (Sacubitril/Valsartan) — Heart Failure
2025 Revenue: $7.75B (-45% Q4 cc) | Generic entry Q3 2025 (MSN Pharmaceuticals). Revenue collapsed -45% in Q4 2025. Largest patent expiry in Novartis history. Patient Finder would apply to generic revenue (~$80-180/patient vs $320-600 branded) — not economically viable.
Promacta/Revolade (Eltrombopag) — ITP
AB-rated generics available (Camber May 2025, Teva Nov 2023, Annora April 2024). ITP generally well-diagnosed via routine CBC. Small market even without generics.
Kisqali (Ribociclib) — Breast Cancer
2025 Revenue: ~$5B est. | Mammography screening standard (65-70% compliance USA). Diagnostic delay minimal (weeks). Underdiagnosis <5%. Growth from adjuvant expansion in already-diagnosed early-stage patients, not finding undiagnosed.
Leqvio (Inclisiran) — ASCVD/Cholesterol
2025 Revenue: $335M (+46% cc) | Cholesterol screening routine (lipid panels standard). NOT finding undiagnosed ASCVD — this is treatment intensification (finding undertreated known ASCVD). Cholesterol is NOT "undiagnosed."
Xolair (Omalizumab) — Asthma/Urticaria
2025 Revenue: $1.723B (-8% cc Q4) | Asthma well-diagnosed via spirometry. Chronic urticaria well-diagnosed (visible hives). Biosimilar competition active in EU (Celltrion's OMLYCLO approved March 2025).
Pluvicto (Lutetium Lu 177 vipivotide) — mCRPC
2025 Revenue: $2.0B (+42% cc) | Treats late-stage mCRPC in patients diagnosed with prostate cancer years earlier (5-10 years from initial diagnosis to mCRPC). No "undiagnosed mCRPC" population. If Ada wants prostate cancer, focus on early-stage PSA screening (not Pluvicto-specific).
Kymriah (Tisagenlecleucel) — Refractory ALL/DLBCL
2025 Revenue: $400M (-14%) | CAR-T treats refractory disease in diagnosed patients (fourth-line+ therapy). ALL/DLBCL diagnosed via routine labs/imaging years before CAR-T consideration.
Tafinlar + Mekinist (Dabrafenib + Trametinib) — BRAF+ Cancers
2025 Revenue: $540M | Requires BRAF testing AFTER cancer diagnosis. Melanoma generally well-diagnosed (visible skin lesions). NSCLC diagnosed via imaging/biopsy. NOT finding undiagnosed cancer — finding eligible biomarker subtype.
Tabrecta (Capmatinib) — MET+ NSCLC
2025 Revenue: ~$70M est. | Ultra-niche biomarker (~3-4% of NSCLC). MET testing happens AFTER NSCLC diagnosis.
Piqray (Alpelisib) — PIK3CA+ Breast Cancer
2025 Revenue: $81M (-28% cc) | Genetic testing AFTER breast cancer diagnosis. Declining sales.
Iqirvo (Elafibranor) — PBC
NOT A NOVARTIS PRODUCT (Ipsen). Developed by GENFIT, marketed by Ipsen. Excluded entirely from Novartis Patient Finder analysis.
Vijoice (Alpelisib for PROS)
Ultra-rare orphan drug (PIK3CA-Related Overgrowth Spectrum). Prevalence unknown (likely hundreds to low thousands USA). Too small for Patient Finder scale. No revenue data available.
Positioning:
Value Proposition: Complementary profiles demonstrate both SCALE (Cosentyx: hundreds of thousands) and PRECISION (Fabhalta: ultra-rare cases). Both have 12-year delays and excellent Ada surface ability.
Combined Opportunity (USA):
Kesimpta: "Relapsing MS Early Detection"
Opportunity: $106M-465M total (USA)
Challenge: Shorter delays (1-2 years), Novartis focused on switching patients rather than finding undiagnosed
Timing: After successful AS + PNH proof of concept
Best Patient Finder opportunities have:
| Region | Priority | Rationale |
|---|---|---|
| USA | HIGHEST | Highest per-patient revenue, best data infrastructure, largest absolute numbers |
| DACH | MODERATE | 100M population, good infrastructure, pre-generic timeline for some drugs |
| Rest of World | LOWER | Focus USA/DACH first, expand after proof of concept |